01—Abstract
Summary
Summary of the 10-K filed February 20, 2009. Cited figures are marked; the original filing is the authoritative source.
Bristol-Myers Squibb Company (BMY) reported significant strategic divestitures and acquisitions in 2008, including the sale of its ConvaTec business for $4.1 billiona, which contributed a substantial $2.0 billion gain after tax.
The company also acquired Kosan Biosciences for oncology product development. These moves indicate a strategic shift towards a more focused biopharmaceutical business. Productivity Transformation Initiatives (PTI) were underway, aiming for $2.5 billionb in annual savings by 2012 through operational efficiencies and cost reductions.
Financially, net sales from continuing operations grew by 13%c year-over-year, driven by strong performance in key products like PLAVIX and ABILIFY. Despite facing ongoing challenges from generic competition, particularly with the expiration of data protection for PLAVIX in the EU, BMY demonstrated resilience and growth through strategic alliances and product pipeline development.
02—Key points
Key Highlights
- Divestiture of ConvaTec business for $4.1 billion, resulting in a $2.0 billion after-tax gain, bolstering the company's financial flexibility.
- Acquisition of Kosan Biosciences to enhance its oncology pipeline.
- Productivity Transformation Initiative (PTI) aims for $2.5 billion in annual cost savings by 2012, demonstrating a focus on operational efficiency.
- Net sales from continuing operations increased by 13% to $20.6 billion, driven by strong performances in PLAVIX (+18%) and ABILIFY (+30%).
- Significant R&D investment of $3.6 billion in 2008, underscoring commitment to innovation and future growth.
- Sale of ImClone shares for approximately $1.0 billion, contributing to improved net cash position.
- Net cash position improved significantly to $1.5 billion due to divestiture proceeds and operating cash flows, a substantial turnaround from net debt in the prior year.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2008, Bristol Myers Squibb Co kept $0.30.
- Revenue$17.71B100.0%
- Cost of revenue−$5.32B30.0%
- Gross profit$12.40B70.0%
- Operating costs−$9.70B54.8%
- Operating income$2.70B15.2%
- Interest, other & tax$2.55B14.4%
- Net income$5.25B29.6%
Where FY2008 revenue went
$17.71B- Cost of revenue: $5.32B, 30% of revenue
- SG&A: $4.14B, 23% of revenue
- R&D: $3.51B, 20% of revenue
- Operating income: $2.70B, 15% of revenue
- Other operating costs: $2.05B, 12% of revenue
Kept 15% as operating income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2008filed February 20, 2009Financial Statements
FY2008 against FY2007
| Line item | FY2008FY2007 | Change |
|---|---|---|
| Revenue | $17.71B$15.62B | +13.4% |
| Cost of Revenue | $5.32B$4.92B | +8.1% |
| Gross Profit | $12.40B$10.70B | +15.9% |
| R&D Expenses | $3.51B$3.16B | +11.1% |
| SG&A Expenses | $4.14B$3.94B | +5.0% |
| Operating Expenses | $12.94B$13.09B | −1.2% |
| Operating Income | $2.70B$1.30B | +108.1% |
| Interest Expense | $310.00M— | — |
| Net Income | $5.25B$2.17B | +142.4% |
| EPS (Basic) | $2.64$1.09 | +142.2% |
| EPS (Diluted) | $2.62$1.09 | +140.4% |
05—Questions
Frequently Asked Questions
What were the major strategic moves made by Bristol-Myers Squibb in 2008?
Bristol-Myers Squibb made significant strategic divestitures and acquisitions in 2008. Notably, they divested their ConvaTec business for $4.1 billion, which resulted in a substantial $2.0 billion after-tax gain. They also acquired Kosan Biosciences to strengthen their oncology pipeline and sold their ImClone shares for $1.0 billion.
How did key products perform in 2008, and what is the outlook for PLAVIX and ABILIFY?
Key products like PLAVIX and ABILIFY drove significant growth in 2008. PLAVIX sales increased by 18% to $5.6 billion, and ABILIFY sales grew by 30% to $2.2 billion. The company faces challenges with PLAVIX due to the expiration of data protection in the EU, but the strong U.S. sales performance and ongoing patent litigation efforts suggest continued focus on maximizing its value.
What is the purpose of the Productivity Transformation Initiative (PTI)?
The Productivity Transformation Initiative (PTI) is designed to fundamentally change how Bristol-Myers Squibb operates its business. The goal is to achieve $2.5 billion in annual productivity cost savings and cost avoidance by 2012 through measures like simplifying operations, standardizing processes, rationalizing the manufacturing network, and improving overall cost efficiency.
How did the company's financial position change in 2008?
The company's financial position significantly improved in 2008. Divestitures, particularly the sale of ConvaTec, and the sale of ImClone shares generated substantial cash proceeds. This, combined with strong operating cash flow, allowed BMY to move from a net debt position in 2007 to a net cash position of $1.5 billion by the end of 2008, while also funding dividends and capital expenditures.
06—Continue